[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-358880-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-358880-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","risk-stratification-of-in-hospital-venous-thromboembolism-for-urological-cancers-a-multicenter-retrospective-study","Risk stratification of in-hospital venous thromboembolism for urological cancers - a multicenter retrospective study","","Current predictive models for venous thromboembolism (VTE) show limited performance for patients with urological cancer. A retrospective multicenter study was conducted to establish and validate an in-hospital VTE risk stratification model. Clinical data from 735 urological cancer patients were analyzed between January 2019 and December 2024, with VTE and non-VTE groups used to develop a logistic regression nomogram. Model discrimination and calibration supported clinical utility, with external validation showing reliable performance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/risk-stratification-of-in-hospital-venous-thromboembolism-for-urological-cancers-a-multicenter-retrospective-study/358880/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/risk-stratification-of-in-hospital-venous-thromboembolism-for-urological-cancers-a-multicenter-retrospective-study/358880.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are existing VTE prediction models limited for urological cancer patients?","Question",{"text":63,"@type":64},"Existing predictive models are not sufficiently accurate for estimating VTE risk in patients with urological cancer, motivating the need for a dedicated risk stratification model.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the risk stratification model developed?",{"text":68,"@type":64},"The study analyzed clinical data from 735 urological cancer patients across four Chinese hospitals, forming VTE and non-VTE groups and building a logistic regression model with LASSO-selected variables, visualized as a nomogram.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the model perform in validation, including external validation?",{"text":72,"@type":64},"Discrimination was supported by AUC values of 0.933 (training), 0.900 (validation), and 0.857 (external validation), alongside good calibration and decision curve results indicating higher net benefit than treat-all or treat-none strategies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},358880,1790624438,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Risk stratification of in-hospital venous thromboembolism forurological cancers: a multicenter retrospective study  \nZhaoyang Li*, Tonghe Zhang*, Guangbin Zhu, Haishan Shen,  \nMinghao Zhang, Huayu Wang, Huitang Yang, Hailong Hu and Yankui Li  \nAbstract  \nBackground: The current predictive models for venous thromboembolism (VTE) have limitations in predicting VTE risk in patients with urological cancer.  \nObjectives: To establish and validate a risk stratification model for in-hospital VTE in patients with urological cancer.  \nDesign: Retrospective, multicenter study.  \nMethods: The clinical data of 735 patients with urological cancer in the Department of Urology at four hospitals in China between January 2019 and December 2024 were analyzed. VTE (n = 147) and non-VTE (n = 588) groups were formed based on inclusion and exclusion criteria to develop a predictive model for VTE in patients with urological cancer.  \nResults: In this study, we developed a risk stratification model using a logistic regression based on variables selected by LASSO and constructed a nomogram to visualize the model. The areas under the receiver operating characteristic curve for the training, validation, and external validation cohorts were 0.933 (95% confidence interval (CI): 0.909–0. 957), 0.900 (95% CI: 0.850–0. 950), and 0.857 (95% CI: 0.776–0. 938), respectively. The corresponding Brierscores for them were 0.070, 0.089, and 0.200. The calibration curve indicated good model performance. Decision curve analysis evaluated the clinical utility of the model and showed that it provided a higher net benefit than the “treat-all” and “treat-none” strategies across a wide range of threshold probabilities, supporting its potential clinical usefulness. Conclusion: A predictive model was developed to estimate the risk of in-hospital VTE inpatients with urological cancer, enabling personalized assessment and guiding preventive strategies. Further studies are needed to better validate our model.  \nKeywords: D-dimer, predictive models, risk factors, urological cancers, venous thromboembolism  \nReceived: 31 May 2025; revised manuscript accepted: 14 February 2026.  \nIntroduction  \nVenous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), represents two clinical manifestations of the same disease at different stages and locations.1 Acute PE is particularly insidious—characterized by high rates of mortality, misdiagnosis, and missed diagnoses—and is a significant  \ncause of unexpected in-hospital and perioperative mortality.2,3 Moreover, VTE is the second leading cause of death in patients with cancer and a significant cause of increased mortality in patients with urological cancer.4–6 The incidence of VTEin patients with urological cancer remains relatively high at 2.5%–7.9% in those with bladder cancer, 1.7%–5.3% in kidney cancer, 2.0%–2.2%  \nTherAdv Med Oncol 2026, Vol. 18: 1–13  \nDOI: 10. 1177/  \n17588359261430135 © The Author(s), 2026. Article reuse guidelines:  \n[sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondence to:  \nHailong Hu  \nDepartment of Urology, The Second Hospital of  \nTianjin Medical University,  \nTianjin 300211, China  \nTianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin 300211, China  \n[huhailong@tmu.edu.cn](huhailong@tmu.edu.cn)[ ](huhailong@tmu.edu.cn)Yankui Li  \nDepartment of Vascular Surgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, China  \nCenter for Cardiovascular Diseases, The Second Hospital of Tianjin Medical University, Tianjin 300211, China  \n[yankuili@tmu.edu.cn](yankuili@tmu.edu.cn)  \nZhaoyang Li Tonghe Zhang Huitang Yang  \nDepartment of Vascular Surgery, The Second Hospital of Tianjin Medical University, Tianjin, China Center for Cardiovascular Diseases, The Second Hospital of Tianjin Medical University, Tianjin, China  \nGuangbin Zhu  \nDepartment of Urology, Tianjin Hospital, Tianjin, China  \nHaishan Shen  \nDepartment of Urology, Ch","cbCaiaqSrUIysGpu","https://ap.wps.com/l/cbCaiaqSrUIysGpu","pdf",1159559,13,"English","# Abstract\n## Background and Objectives\n## Design and Methods\n## Results and Conclusions","[{\"question\":\"Why are existing VTE prediction models limited for urological cancer patients?\",\"answer\":\"Existing predictive models are not sufficiently accurate for estimating VTE risk in patients with urological cancer, motivating the need for a dedicated risk stratification model.\"},{\"question\":\"How was the risk stratification model developed?\",\"answer\":\"The study analyzed clinical data from 735 urological cancer patients across four Chinese hospitals, forming VTE and non-VTE groups and building a logistic regression model with LASSO-selected variables, visualized as a nomogram.\"},{\"question\":\"How did the model perform in validation, including external validation?\",\"answer\":\"Discrimination was supported by AUC values of 0.933 (training), 0.900 (validation), and 0.857 (external validation), alongside good calibration and decision curve results indicating higher net benefit than treat-all or treat-none strategies.\"}]","Risk stratification of in-hospital venous thromboembolism for urological cancers - a multicenter retrospective study | PDF",1790135537,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4aa998a4a7a527115b7dd87c2e749ad.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/470c8496db76d786e5b90a801040781a.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41e20245015feafc4ff0b71d50edec09.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d1d6359f2b6aba1dc27ddd59be9859f.webp",980,1306]